Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.72 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | RHOC | P08134 | 1/20 | 0.58 |
| ▸ | RHOA | P61586 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23304103 | 0.88 | P2RX1 (1.00) | P2RX1NPC1RAB9ALMNAMAPT | |
| SCHEMBL826721 | 0.87 | MAPT (0.83) | P2RX1NPC1RAB9ALMNAMAPT | |
| SCHEMBL2564890 | 0.84 | NPC1 (1.00) | P2RX1NPC1RAB9ALMNAMEN1 | |
| SCHEMBL6796839 | 0.84 | TP53 (0.73) | P2RX1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2859341 | 0.84 | MEN1 (0.78) | P2RX1NPC1RAB9ALMNAMAPT | |
| SCHEMBL6559364 | 0.84 | PTGS1 (1.00) | P2RX1NPC1RAB9ALMNAMAPT | |
| SCHEMBL10804897 | 0.83 | MEN1 (0.81) | P2RX1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2064051 | 0.82 | TRPV1 (0.73) | NPC1RAB9ALMNAMAPTMEN1 | |
| SCHEMBL8773726 | 0.82 | MEN1 (0.69) | P2RX1NPC1RAB9AMEN1KMT2A | |
| Iodide SCHEMBL30758553 | 0.82 | NPC1 (0.96) | P2RX1NPC1RAB9ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181987-B9 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2181987-B1 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8324395-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2181987-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | P2RX1 3483/4885NPC1 3493/4885RAB9A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.